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EFFECTS OF FILTRATION STERILIZATION ON THE STABILITY OF 
KETAMINE, SELECTED BENZODIAZEPINES AND METABOLITES IN 
FEMALE URINE 
LIN ZHEN 
ABSTRACT 
 
Benzodiazepines (Benzos) and ketamine (K) are compounds that have been 
encountered in Drug-Facilitated Sexual Assault (DFSA) cases. Due to the intimate nature 
of these crimes, evidence collection is often postponed due to delays and/or reluctance in 
reporting these crimes.  Further delays in analysis may be encountered in laboratories 
with large caseloads and/or backlogs.   Drug identification in biological samples is 
important to determine whether victims knowingly or unknowingly took an impairing 
substance, however, the results could be negative due to chemical degradation over a 
long storage period.  The purpose of this project was to study if degradation could be 
prevented with a new preservation method at the time of collection.   
Urine samples were prepared by the addition of K and metabolites and selected 
benzos and metabolites that were subjected to different sample pre-treatment techniques, 
and were analyzed after storage at room temperature (25°C), refrigerator (4°C) and 
freezer (-20°).  The samples were either pre-treated with preservative (0.5% toluene) or 
filtration sterilization (sterile filter kit) within two hours after sample collection, and a 
control group with no pre-treatment was incorporated into the study for comparison. The 
changes in concentrations over 50 days (Benzos group) and 210 days (K group) were 
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evaluated between different pre-treated methods and different temperature conditions.  
Sample that were treated with 0.5% toluene showed the most degradation: 44% of 
oxazepam and 96% of diazepam degraded over 10 days, and 80% of dehydronorketamine 
degraded after storage of 150 days regardless the temperature conditions.  Clonazepam 
and flunitrazepam concentrations were reduced by 80% of the original concentration 
when stored at room temperature for 10 days.  The major benzodiazepines evaluated in 
this study were stable when stored in the freezer.  In K group, ketamine and norketamine 
that were stored at room temperature and refrigerated over 210 days were stable, however, 
degradation was observed after 150 days when the samples were stored in the freezer.   
There was no statistically different change observed among the samples pre-
treated with or without filtration sterilization.   Each sample pH was measured and it was 
determined that those stored at room temperature had an average pH of 8.5, while 
samples stored in the refrigerator and freezer had an average pH of 6.7 and 6.5, 
respectively.  This finding revealed that pH could be the major factor affecting compound 
degradation rather than the bacterial contamination with high pH contributing to 
degradation, and low pH potentially preventing sample lost.  
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1 INTRODUCTION  
Drug-Facilitated Sexual Assault (DFSA), often referred to “date rape” or “drug 
rape” happens when a victim is impacted by alcohol and/or drugs that cause them to be 
unconscious and unable to give consent to sexual activity. (1, 2)  There are more than 50 
known or suspected substances that have been reported in DFSA crimes, and many of 
these substances can be obtained easier than illicit drugs.  Some prescription medications 
or the over-the-counter pharmaceuticals impact the user’s mental condition with long 
duration effects. (3)  Gamma-hydroxybutyrate (GHB), flunitrazepam (Rohypnol®) and 
ketamine (K) have been reported as the most common date rape drugs by the United 
States (U.S.) Department of Health and Human Services, Office on Women’s Health 
(Table 1-1).  These date rape drugs are colorless, flavorless and odorless and can be 
easily added into any drink without the awareness of the victim.  The adverse effects of 
these substances include drowsiness, dizziness, sedation, unconsciousness and confusion, 
and some of them can also cause hallucination. (4, 5)  These adverse effects are 
detrimental to the investigation as most victims regain don’t regain consciousness for 
hours after the event. (2)  The later the victims are examined, the less evidence is likely to 
be collected.  
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Table 1-1 Examples of substances detected in urine of DFSA victims. (6) 
Drug Usual Duration of Detection in Urine1 
Amphetamines 1-3 days 
Barbiturates 2-7 days 
Benzodiazepines 2-7 days 
Benzoylecogonine 1-2 days 
Cannabinoids 2-5 day (single use) 
Carisoprodol 1-2 days2 
Chloral hydrate 1-2 days2 
Clonidine 1-2 days2 
Cyclobenzaprine 1-2 days2 
Diphenhydramine 1-2 days2 
Ethanol Less than 1 day 
Gamma hydroxybutyrate Less than 1 day2 
Ketamine 1-2 days2 
Meprobamate 1-2 days2 
Opioids 2-3 days 
Scopolamine 1-2 days2 
1Estimate of the duration of detection, with the use of methods more sensitive than typical drug screening. 
Actual detection will depend on individual metabolism, dose, and concentration in specimen. Also, assays 
vary in sensitivity and specificity depending on the laboratory, so it is important to consult with the 
laboratory for definitive information. 
2Specific information not available; duration given is an estimate. 
 
There were 330,170 and 284,350 rape/sexual assault crimes in the U.S. in 2013 
and 2014, but the percent of victimizations reported to police were only 45.6% and 
46.0%, respectively. (7)  A study from Wayne State University and Michigan State 
University found that only 58.6% of the sexual assault kits (SAKs) collected by sexual 
assault nurse examiners (SANE) in sexual assault crimes were submitted to the crime 
laboratory within a large Midwestern county. (8)  Patterson et al. also indicated in their 
study that the SAKs were more likely to be submitted (a) when there were documented 
physical injuries; (b) if the law enforcement agency had a greater collaboration with the 
SANE program; or (c) if there was no evidence of any cleaning by the victims themselves. 
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(8)  DFSA victims are less likely to have physical injuries because they can’t resist due to 
the effects of the drugs, thus decreasing the likelihood that their case is thoroughly 
investigated. 
Even though SAKs may be submitted, not all of them are examined.  Backlog, or 
evidence submitted to a crime laboratory that remains untested after 30 days, can occur 
when agencies don’t believe it will help identify the assailant, or when the agency lacks 
resources. (9)  Backlog is a very challenging problem for the analysis of biological and 
chemical evidence because the evidence can degrade over time.  Degradation starts at the 
time of sample collection, and compounds could become undetectable if the samples 
were highly degraded. Reports from National Institute of Justice (NIJ) revealed that the 
combined untested SAKs from Los Angeles Sheriff’s Department (LASD) and Los 
Angeles Police Department (LAPD) were from 10,895 cases in the fall of 2008 and the 
untested SAKs from Houston Police Department (HPD) were from 6,663 cases in 2010. 
(10, 11)  
The goal of this project was to study a new technique to preserve the samples at 
the time of collection, and maintain the concentration of samples over time.  The new 
preservation method was investigated and compared with a traditional anti-bacterial 
preservative method, and changes in concentrations were used to determine if 
degradation was prevented.  Ketamine (K), selected benzodiazepines (Benzos) and 
metabolites were used to evaluate effects of the new preservation method in this project.  
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1.1 Filtration Sterilization 
In addition to blood, urine is an essential biological material to be collected in 
DFSA crimes. However, unlike blood specimens, urine specimens are more easily to be 
contaminated with bacteria, because: (a) they can be contaminated with naturally 
occurring and/or infectious bacteria; (b) their aseptic collection into a test tube is nearly 
impossible; (c) and they can be exposed to high ambient temperatures during collection 
and transportation. (12)  Remarkable contamination has also been observed in 
postmortem cases.  The contamination of bacteria can potentially degrade the drugs 
during the storage.  Escherichia coli (E. coli) is the most common bacteria found in urine 
with a size of approximately 1 µm in width and 3 µm in length. (13)  E. coli has a rapid 
growth rate such that it could grow at least 99% of the bacterial population with the mean 
minimum generation time of 21.7 +/- 0.6 min in the bladder model over 24 h. (14)  A 
large population of E. coli can be accumulated within one day, which is a severe factor to 
the drug degradation. 
Filtration sterilization (FS) is the new preservation method, which is designed to 
eliminate or minimize the bacterial population at the time of collection to stop or reduce 
the degradation caused by bacteria.  A filter membrane pore size of 0.2 µm was chosen 
based on the overall size of E. coli, so that the filter could remove the E. coli effectively.  
In addition, toluene is a common antibacterial preservative used for urine specimens, and 
it has been found that calcium, oxalate, magnesium, phosphate, sodium, urate and pH of 
the urine samples could be effectively preserved with its use. (15)  A set of samples pre-
treated with toluene was analyzed to compare the effects between old and new 
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preservation methods, and another set of samples without any pre-treatment was also 
analyzed as a control.   
 
1.2 Benzodiazepines 
 Benzodiazepines (Benzos) are a class of anxiolytic drugs that bind to the Benzos 
response sites located at the interface of alpha and gamma-2 subunits of GABA receptors. 
(4)  The binding activates the chloride ion (Cl-) channel, and the entry of Cl-
hyperpolarizes the cell. (4)  This hyperpolarization can be enhanced with the binding of 
Benzos due to the neural depolarization that has been inhibited. (5)  
The pharmaceutical effects of Benzos include sedation, hypnosis, anesthesia, 
anticonvulsant effects, muscle relaxation and effects on respiration and cardiovascular 
function that depend upon the correlation and affinity between different Benzos and the 
GABA receptors. (4, 16)  Hence, there are many therapeutic uses in this class of drugs, 
including for treating anxiety disorders, insomnia, seizures, pre-anesthetic and short 
medical/surgical procedures, muscle relaxation, acute mania and symptoms of physical 
dependence. (5)  Even though the effects of Benzos are various, drowsiness and 
confusion are the major and common adverse effects of Benzos, regardless the type of 
Benzos.  Table 1-2 illustrates the dosage and direction of the common prescribed Benzos 
for sedation and hypnosis.  It is easy to find that the clinical dosage of Benzos is usually 
very little, and that is a huge benefit to sexual assailants because it is easy to add into any 
drink without being caught, and the small pills dissolve quickly.  
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Table 1-2 Dosage common prescribed Benzos. (16) 
Sedation Hypnosis 
Drug Dosage Drug Dosage (bedtime) 
Alprazolam 
0.25-0.5 mg 2-3-times 
daily Estazolam 0.5-2 mg 
Chlordiazepoxide 10-20 mg 2-3 times daily Lorazepam 2-4 mg 
Diazepam 5 mg twice daily Quazepam 7.5-15 mg 
Halazepam 20-40 mg 3-4 times daily Temazepam 7.5-30 mg 
Lorazepam 1-2 mg once or twice daily Triazolam 0.125-0.5 mg 
Oxazepam 15-30 mg 3-4 times daily   
  
The microsomal oxidation and conjugation occur sequentially in the Benzos 
metabolism, and many of the oxidation products (phase I metabolites) are 
pharmacologically active with a long half-life.  Table 1-3 illustrates the half-life of parent 
compounds, which is about 1-3 h on average, but their major metabolites have an average 
of 40 h half-life.  Most of the major metabolites are pharmaceutical active, which 
explains why the victims can remain unconsciousness for hours.  Parent compounds 
would be hard to detect, and only metabolites could be found after the victims regained 
consciousness.  This attribute makes a challenge for the analysts on the interpretation of 
the results.  Structurally, this class of drugs shares a diazepine ring fused with a benzene 
ring, and the structural similarity between different Benzos explains why they have 
common effects of sedation and hypnosis.  The structural similarity also results in Benzos 
sharing common metabolites, and oxazepam is one of them.  The confirmation of 
oxazepam is often used as the indication for the use of Benzos. 
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Table 1-3 Pharmacokinetic properties of Selected Benzos in humans. (16) 
Drug Tmax1 (hours) T1/22 (hours) 
Alprazolam 1-2 12-15 
Chlordiazepoxide 2-4 15-40 
Diazepam 1-2 2—80 
Flurazepam 1-2 40-100 
Lorazepam 1-6 10-20 
Oxazepam 2-4 10-20 
Temazepam 2-3 10-40 
Triazolam 1 2-3 
1Time to peak blood level 
2Includes half-lives of major metabolites 
 
The other challenge of Benzos detection is compound stability.  The parent 
compounds are less likely to be detected due to the short half-life, but the metabolites 
could be found if the specimens were collected as early as the victim regained 
consciousness and was examined in the hospital.  As described previously, the SAKs 
might not be submitted to the laboratory and/or analyzed without any delay.  The critical 
point is the stability of Benzos and metabolites, and it has been found that the 
concentrations of Benzos decrease dramatically over time.  El Mahjoub et al. studied the 
stability of clonazepam, midazolam, flunitrazepam and oxazepam in whole blood 
samples stored at four different temperatures.  There was no significant change in the 
concentrations of samples stored at -20°C and -80°C, but they found the concentrations 
of the selected Benzos decreased at least 90% for the samples prepared at a low 
concentration (250 ng/mL) and more than 50% for the samples prepared at a high 
concentration (1000 ng/mL) if the samples were stored at either room temperature or 4°C. 
(17)  Therefore, it is important to develop an effective preservation method to prevent 
degradation. 
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1.3 Ketamine 
 Ketamine (K), [2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one], is one of 
the anesthetic agents used for general anesthesia, and no specific receptor has been 
identified for K if administrated intravenously (IV). (16, 18)  The properties of K include 
anesthetic and analgesic, and it is the only anesthetic agent that has both properties. (16)  
However, the postoperative psychic effect is severe with a high dose injection (1-2 mg/kg 
IV), and therefore, the use of low dose K (0.1-0.25 mg/kg IV) with a combination of 
preanesthetic drugs, such as Benzos, becomes favored. (16)  The lower the dose, the 
smaller the pills, which make it easier for assailants to add them to drinks without any 
awareness.   
 The excitation of glutamate at the N-methyl-D-aspartate (NMDA) receptor 
complex is inhibited by K, and this inhibition triggers the open/close of the ion channels 
to produce anesthesia. (19)  The metabolism of K occurs in the liver and is catalyzed by 
the cytochrome P450 enzymes that undergo N-demethylation to its active metabolite, 
norketamine (NK), which also contributes to the analgesic effects; the second metabolite 
produced is dehydronorketamine (DNK), which is formed by the oxidation of the 
cyclohexanone ring. (20)  The bioavailability of K is about 8%-17% due to the first-pass 
metabolism in liver, and its half-life is only a few minutes. (20-22)  However, the first 
metabolite NK, which has one third of potency as K, has a  half-life that is much longer 
than K. (23)  Fanta et al. found that the half-life of NK was 342 min after an initial oral 
dosing, which could be detected up to an average of 3 days post-dose, and DNK was 
confirmed to be detected up to 10 days. (21, 24)  Therefore, DNK is an indicator to report 
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that K was very likely consumed if neither K nor NK was detected. 
 As mentioned previously, the dose of K needs to be high to cause the sufficient 
anesthetic effect.  A 60-kg (132 lbs.) person will need to be injected 60-120 mg of K to 
experience the effect, and if a concentration of 100 mg/mL of K is available in the market, 
the 60-kg individual will need to consume at least 3.5 mL (solid form might be smaller in 
size) orally to experience the intended effects for a few minutes.  The cost is also an 
important factor.  Therefore, a combination of K and other drugs is favored not only by 
the surgeons but also the assailants.  The analysis and interpretation of K becomes more 
complicated with the use of other drugs, because: (a) a sensitive screening test has to be 
manufactured; (b) the efficiency of the extraction method should be evaluated for the 
common date rape drugs; (c) a comprehensive instrumental analysis method must be 
developed; (d) the clinical and adverse effects should be studied for the combinational 
use of K and other drugs; and (e) essential training for the complex interpretation must be 
provided to the analysts. 
 
1.4 Zolpidem  
 Zolpidem (Z) is a hypnotic substance prescribed for insomnia treatment. (25)  
Zolpidem targets the same receptors as Benzos, but it has no structural similarity to 
Benzos (Figure 1-1), which cannot be used as an anticonvulsant or muscle relaxant. (4)  
The therapeutical dosage of Z is 5-10 mg, which has a maximum duration time of 1-3 hrs 
(time to peak blood level) without active metabolite. (16)  The major metabolite of Z is 
zolpidem carboxylic acid (ZCA), but its stability is unclear.  Eighty percent of Z is 
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metabolized to ZCA by cytochromes P450 enzymes, and the use of Z could be confirmed 
if ZCA was detected. (26)   The use of Z could be confirmed if M-3 metabolite was 
detectable.  The duration time is short compared to the other compounds, but it is one of 
the common date rape drugs, therefore, the analysis of Z was also included in this project.  
(A)  (B)  
Figure 1-1 Structures of benzodiazepine and zolpidem. (27, 28) 
(A)The structure of benzodiazepine 
(B)The structure of zolpidem 
 
 
1.5 Purpose of This Study  
The purpose of this project was to evaluate the effects of FS and toluene on 
preventing compound degradation in the urine specimens.  To date, there are many 
analytical methods that have been developed using gas chromatography – mass 
spectrometry (GC/MS), liquid chromatography – mass spectrometry (LC-MS) or other 
sensitive instruments and techniques for the detection and quantification of the suspected 
substances, even in a trace amount.  However, the prevention of degradation in the post-
collection specimens have not been well studied.  In this study, the analytes were divided 
into two groups, K group and Benzos group, to evaluate the effect of FS on the stability 
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of selected compounds.  Ketamine (K), norketamine (NK) and dehydronorketamine 
(DNK) were chosen for the K group, and Benzos group included alprazolam, clonazepam, 
diazepam, flunitrazepam, lorazepam, midazolam, nordiazepam, oxazepam, temazepam 
and zolpidem (Z).  Two groups of samples were prepared and analyzed by using different 
extraction and analytical methods. 
 
2 EXPERIMENTAL  
2.1 Instrument and Extraction Technique Theory 
2.1.1 Liquid Chromatography-Mass Spectrometry 
 Liquid chromatography (LC) is an analytical technique used to separate and 
resolve compounds from a mixture.  The components of a LC system include the mobile 
phase reservoir(s), a degasser, a pump, a mixer, an autosampler, a column, a detector and 
a data collection device. (29)  The separation is based on the interaction between 
compounds, stationary phase and mobile phase.  The polarity of the target compounds 
determines the choice of column (stationary phase) and the mobile phase.  The column 
(stationary phase) is the most important element of the sample introduction in the LC 
system, which is a solid stationary phase packed with the adsorbent material.  The 
selected column must be similar in polarity to the target compounds, so that the 
compounds can move slower due to the higher affinity to the stationary phase.  The 
mobile phase is the key to conduct the movement of compounds in the LC column.  The 
polarity of the mobile phase can be changed by changing the concentration of the organic 
solvent to alter the proportion of the aqueous and organic solutions.  The compounds can 
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be moved faster and eluted when the polarity of the mobile phase reaches a similar 
polarity as the compounds.  Therefore, the separation can be optimized by utilizing a 
gradient elution if more than one mobile phase is used.   
 Mass spectrometry (MS) is a sensitive analytical technique often used to identify 
compounds by measuring their mass-to-charge ratio (m/z) after they are separated by the 
LC system, and a tandem mass spectrometer (MS/MS) is a common detector used.  The 
difference between MS and MS/MS is that one MS is attached to another MS, which can 
improve the sensitivity, specificity and accuracy by (a) removing matrix interferences; (b) 
providing reliable confirmation; (c) allowing the selective quantitation of target 
compounds in high background samples; and (d) getting better signal/noise in complex 
matrices than the single MS. (30)  The compounds must be ionized before they are 
introduced to the MS system, and the ionization is provided by electrospray ionization 
(ESI).  The liquid sample is injected through a capillary, and ESI produces ions while the 
droplets are evaporating. (31)  The ionization process is to ensure the parent ions can be 
recognized by the MS, as well as be fragmentized later in the collision chamber.  
 A triple quadrupole configuration is set up linearly in the MS/MS instrument.  
The first quadrupole (Q1) is the mass filter to filter anything else besides the precursor 
ion that has been identified in the compound optimization step (detail explanation is in 
2.2.6), and then the precursor ion is accelerated to the second quadrupole (Q2).  The 
collision cell is located in Q2 where the precursor ion is dissociated into fragment ions.  
The fragment ions are then accelerated into the third quadrupole (Q3) which is another 
mass filter for the selected product ions.  The product ions are also selected and identified 
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in the compound optimization step, and they are detected based on their m/z. 
 
2.1.2 Solid Phase Extraction 
 Solid phase extraction (SPE) is a sample preparation technique used to purify 
compounds prior to sample introduction.  In drug or toxicology analysis, plant materials, 
substances in the solid or the liquid form and biological samples are commonly seen.  
The size of the molecules in these matrices is relatively large, for example, the red blood 
cells have an average size of 8 µm in diameter, and an E. coli cell is approximately 1 µm 
in width by 3 µm in length. (32)  However, a normal LC column has a particle size of less 
than 5 µm and a pore size of 100 Å.  The matrices can cause blockage and damage to the 
column.  In addition, they can also increase the noise in the MS detection and interfere 
with the results.  The use of SPE can remove the impurity and extract compounds from 
samples based on the physical and chemical properties. 
The SPE column is packed with the bonded silica gel, and the selection is based 
on the interactions between the sorbent and the compounds.  The principle for the 
separation of SPE is similar to LC, and the mechanisms include non-polar (hydrophobic 
interactions), polar (hydrophilic interactions), ion-exchange (cation and anion) and mixed 
mode interactions.  The affinity between the sorbent and analytes determines how tight 
the target analytes can be held in the column until they are eluted.  The advantages of 
SPE include (a) solvent, and laboratory time are reduced, but the efficiency is improved 
compared with Liquid-Liquid Extraction (LLE); (b) it is fast and easy to perform; and (c) 
the matrix can be removed or minimized to protect and maintain the cleanliness of the 
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instrument.   
An appropriate SPE method is designed based on the compounds of interest and 
the column as described previously, but there is a general scheme to perform SPE.  The 
first step has been discussed in the previous paragraph, which is also called the selective 
extraction.  In other words, the sorbent must be able to catch and hold all the compounds 
tight while the sample is running through the column.  The second step is called selective 
washing, and solutions must be strong enough to remove the impurity but weak for the 
compounds.  The last step is the selective elution, in which the compounds must be able 
to dissolved in the solvent so that they can be carried while the solvent is eluting. (33) 
  
2.2 Materials & Methods  
2.2.1 Reagents and Standards 
 Ammonium formate, ammonium hydroxide, formic acid, sodium acetate 
trihydrate, high performance liquid chromatography (HPLC) grade methanol (MeOH), 
HPLC grade acetonitrile (ACN), HPLC grade methylene chloride, HPLC grade ethyl 
acetate and hydrochloride acid (HCl) were purchased from Fisher Scientific Inc. 
(Pittsburgh, PA).  Sodium phosphate monobasic, sodium phosphate dibasic, acetic acid 
and HPLC grade isopropanol were purchased from ACROSâ (Geel, Belgium).  Beta-
glucuronidase from limpets (patella vulgate) was purchased from Sigma-Aldrich Inc. (St. 
Louis, MO).  Purified water, referred to as millipore water, was obtained from a Synergy 
UV water system from EMD Millipore/Merck (Darmstadt, Germany).  
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Nuclear fast red stain (Xmas tree stain A) and picroindigocarmine stain (Xmas 
tree stain B) were purchased from SERIâ (Richmond, CA), hematoxylin stain was 
purchased from RICCAâ (Arlington, TX), and eosin Y stain was purchased from 
ACROSâ (Geel, Belgium). 
Individual ampoules of K, NK, alprazolam, clonazepam, diazepam, flunitrazepam, 
lorazepam, midazolam, nordiazepam, oxazepam, temazepam, Z (at a concentration of 1 
mg/mL), DNK, K-d4, NK-d4, diazepam-d5, oxazepam-d5 and Z-d7 (at a concentration of 
100 µg/mL) were purchased from Cerilliant Corporation (Round Rock, TX).  Stock 
standard solutions of these analytes were prepared in methanol or acetonitrile to make a 
concentration of 100 µg/mL.   
 
2.2.2 Urine Specimen and Bacterial Contamination Determination 
The urine specimens were collected from six female donors, and the presence or 
absence of the compounds of interest was confirmed before experiments commenced.  
The bacterial contamination level of the urine specimens was determined by the number 
of bacterial cells.  Each urine specimen was mounted on a glass slide, and enhanced by 
hematoxylin and eosin staining (H&E) and Christmas Tree staining (KPIC) 
techniques.  The slides were examined under 400X magnification for the presence of 
bacterial cells and/or epithelial cells.  The number of bacterial cells per magnification 
field was estimated by counting the number observed in 10 representative fields, 
calculating the average and assigning one of these values: 
0 = no bacterial cells present 
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1+ = few bacterial cells on entire slide; difficult to locate 
2+ = at least one bacterial cell in most of the fields 
3+ = several bacterial cells in most of the fields; easy to locate 
4+ = many bacterial cells in most of the fields 
The urine samples were examined on Day 0 and the last day of analysis to 
determine the original contamination level for each donor and the contamination level 
after aging.   
 
2.2.3 Filtration Sterilization and Samples Preparation 
The filtration sterilization (FS) was performed by using 25 mm GD/X sterile 
syringe filters that were purchased from Sigma-Aldrich Inc. (St. Louis, MO).  The 
samples were pulled into the syringe, and then attached to the syringe filter which is 
equipped with a polyethersulfone membrane (pore size 0.2 µm, diameter 25 mm).  This 
pore size is only half of the minimal size of E. coli, which should be sufficient enough for 
the bacteria based on the previous discussion (section 1.1).  The sample was then pushed 
into the Falcon test tube by passing through the filter, and stored under three different 
temperature conditions: 25°C, 4°C and -20°C. 
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Figure 2-1 Filtration kit. 
 
The samples were prepared by spiking the solution in the urine at a concentration 
of 500 ng/mL, and then the pre-treatments (FS and toluene preservative) were applied to 
the samples prior to storage.  Next, 0.5% of toluene was added to all samples as the 
preservative based on the research from Wu et al. (15)  On the day of analysis, all 
analytes and internal standards (IS) were prepared for the calibration curve and samples.  
For K group, the samples were analyzed on Day 0, Day 150, Day 180 and Day 210.  For 
Benzos group, the samples were analyzed on Day 0, Day 10, Day 30 and Day 50.  Table 
2-1 shows the treatments and storage condition of the specimens.  
Table 2-1 The treatments and temperature condition of the samples. 
Temperature Treatment 
25°C F1 P2 N/T3 
4°C F P N/T 
-20°C F P N/T 
1F – filtration sterilization 
2P – addition of toluene preservative 
3N/T – no treatment 
2.2.4 Solid Phase Extraction  
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The Clean Screen XcelâI columns were used to perform SPE for the Benzos 
group, and the columns were purchased from United Chemical Technologies, Inc. 
(Bristol, PA).  The samples were pre-treated by incubating the combination of 500 µL of 
the urine sample, 500 µL of 100 mM acetate buffer (pH=5) and 20 µL of beta-
glucuronidase at 65°C for one hour.  The samples were cooled to room temperature after 
they were moved from the incubator, and a set of Clean Screen XcelâI columns was 
inserted in the corresponding position of the column rack in the manifold.  The pre-
treated samples were poured into the column sequentially without the adjustment of pH 
and no conditioning step was required in this procedure.  After the samples passed though 
the columns, 3 mL of acetate buffer was added to wash the columns applied with a 
pressure of 5 psi, and a high pressure (>25 psi) was then applied to dry the columns for 5 
min.  Addition of 3 mL methylene chloride was used to wash the columns applied with a 
pressure of 5 psi, and a high pressure (>25 psi) was applied to dry the columns for 10 min 
after the solvent was completely passed though.  Three milliliters of the mixture of ethyl 
acetate and ammonium hydroxide (98:2, v:v) was used to elute the analytes.  The eluate 
was evaporated to dryness at about 45°C, and the dried residue was dissolved with 50 µL 
of the mobile phase, 15 µL of the reconstituent was injected into the LC instrument. 
The Clean Screenâ DAU Extraction columns were used to perform SPE for the K 
group, and the columns were purchased from United Chemical Technologies, Inc. 
(Bristol, PA).  A set of Clean Screenâ DAU Extraction columns was placed in 
corresponding positions of the column rack in the manifold.  The conditioning step was 
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required for this method, thus 1 mL of MeOH and 1 mL of phosphate buffer were added 
sequentially to the columns in this step.  The samples were transferred into the columns 
and allowed to drip by gravitational flow.  The wash steps included 1 mL of DI H2O, 1 
mL of 0.1N HCl and 1 mL of MeOH and were added into the columns sequentially.  A 
high positive pressure (>25 psi) was applied to dry the samples for 5 min.  The base 
elution solvent, a mixture of ammonium hydroxide, isopropanol and ethyl acetate 
(3:20:77, v:v:v), was added to elute the analytes.  The 2-mL eluate was evaporated to 
dryness at approximately 65°C, the dried residue was reconstituted with 50 µL of a 
mixture of ACN and millipore water (50:50, v:v), and 5 µL was injected into the LC 
instrument.  
 
2.2.4 Extraction Recovery 
 In each group, three samples were prepared with the analytes in negative urine at 
the concentrations of 50 ng/mL and 200 ng/mL, and six samples were blank urine.  
Twelve samples were extracted following the respective SPE procedure, and the same 
amount of solutions was added into the eluate extracted from the blank samples prior to 
the evaporation.  After they were dried down, the normal reconstitution step was 
performed, and the samples were analyzed by LC-MS/MS. 
 
2.2.5 HPLC (UFLC) Conditions 
 The LC analysis was performed on a Shimadzu Ultra-Fast Liquid 
Chromatography (UFLC) system consisting of Shimadzu LC-20 AD pumps and a SIL-20 
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auto sampler (Kyoto, Japan).  The LC parameters were optimized after the compounds 
and the source optimization were completed, which will be discussed later (section 2.2.7).  
The analytical column was the 100 X 3.0 mm Phenomenex® Kinetexä 2.6 µm Biphenyl 
100 Å LC column (Torrance, CA), and the guard column was the Phenomenex® 
SecurityGuardäULTRA.  The same column was used for the analysis of both groups, but 
the analytical methods were different.  
 The LC method was based on work from Quintela et al. for the BPZs group. (34) 
The gradient separation was performed with a binary mobile phase consisting with 5 
mmol/L (pH = 3) ammonium formate (mobile phase A) and a mixture of ACN and 5 
mmol/L (pH = 3) ammonium formate (90:10, v:v; mobile phase B) at a flow rate of 400 
µL/min.  Table 2-2 demonstrates the gradient; the total run time was 7 min, and the oven 
temperature was set at 45°C. (34) 
Table 2-2 The concentration gradient of LC-MS/MS for Benzos group. 
Time (min) Mobile phase B (%) 
0 35 
5 80 
6 60 
6.5 35 
 
The LC method was based on the research of Parkin et al. for the K group. (24) 
The gradient separation was performed by using the binary flow mode with a flow rate of 
400 µL/min.  The mobile phase consisted of a gradient of millipore water with 0.1% 
formic acid (mobile phase A) and ACN with 0.1% formic acid (mobile phase B).  Table 
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2-3 demonstrates the gradient; the total run time was 3 min, and the oven temperature 
was set at 40°C. (24) 
Table 2-3 The concentration gradient of LC-MS/MS for K group. 
Time Mobile phase B (%) 
0 30 
0.3 30 
2 40 
2.5 30 
  
2.2.6 MS/MS Detection 
 The MS/MS detection was performed on a SCIEXTM 4000 Qtrap (Framingham, 
MA).  Data analysis was done by using SCIEXTM Analyst® software (version 1.6.2) and 
quantification was done by using SCIEXTM MultiQuant® software (version 3.0).  The 
compounds of interest and source/gas parameters were optimized prior to performing 
analysis.  Only the MS/MS system was turned on while performing the compound 
optimization and the manual optimization mode was used to optimize all compounds.  All 
standards were optimized in positive-ion mode by the direct infusion at a flow rate of 10 
µL/min.  The standards of K, K-d4, NK, NK-d4, alprazolam, clonazepam, diazepam, 
diazepam-d5, flunitrazepam, midazolam, nordiazepam, oxazepam, oxazepam-d5, 
temazepam, Z and Z-d7 were diluted to a concentration of 10 ng/mL in a mixture of 
MeOH and millipore water (50:50, v:v), and the standards of DNK and lorazepam were 
diluted to a concentration of 10 ng/mL in a mixture of ACN and water (50:50, v:v).  The 
first step in manual compound optimization was to confirm the presence of the precursor 
ion by using the Q1 MS scan type, and the syringe pump method was utilized throughout 
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the whole process.  The molecular weight of the parent compound was searched from 
PubChem, and the start and stop dalton (Da) were set to be at -/+ 50 Da of the theoretical 
value, respectively.  The most abundant ion was confirmed to be the precursor ion after a 
3-min scan with a scan rate of 1000 Da/s.  Once the precursor ion was confirmed, the 
major product ions could be searched by using the Product Ion (MS2) scan type.  
Collision energy of 400 v was used to fragment the precursor ion, and the search was 
started from 100 Da.  The three most abundant product ions were continued to optimize 
their parameters, but the ions of 18 Da or 44 Da (water and carbon dioxide, respectively) 
were excluded.  The parameters were optimized by monitoring the best signal for each 
transition while changing the ramp parameter settings, and the parameters include 
declustering potential (DP), collision energy (CE) and collision cell exit potential (CXP).  
Table 2-4 listed the MRM transitions of the compounds from Benzos group and K group. 
For source optimization, the LC system was incorporated with the MS/MS system, 
and the syringe pump method was also utilized.  This step is to ensure the ion source and 
gas are set properly to protect and maintain the cleanliness of the instrument and the 
compounds can be introduced to MS/MS system optimally.  The LC-MS/MS system 
setting remained unchanged but the autosampler was turned off in source optimization.  
The ion source and gas parameters were optimized by monitoring the most intensive 
signal for the individual ion extraction and the total ion extraction chromatographs for the 
compounds of interest while changing the parameters that followed the order of curtain 
gas (CUR), collision gas (CAD), ionspray voltage (IV), ion source gas 1 (GS1), ion 
source gas 2 (GS2) and temperature (TEM).  The source optimization was performed 
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routinely to ensure the optimal results.  The source and gas condition were optimized, and 
the results are listed in Table 2-5. 
Table 2-4 MS conditions for the analytes in Benzos and K groups. 
Compound Q1 Q31 DP CE CXP 
Alprazolam 309 281.1 100 35 15 
  205.2 100 55 10 
Clonazepam 316 270 100 35 20 
  241 100 50 20 
Diazepam 285 154 100 40 13 
  193 100 45 18 
Flunitrazepam 314 268 100 40 13 
  239.2 100 45 18 
Lorazepam 321 275 70 30 15 
  229 70 40 12 
Midazolam 326 291.3 110 37 20 
  223 110 50 15 
Nordiazepam 271 140.3 90 40 10 
  165 90 40 13 
Oxazepam 287 241 90 40 10 
  104 90 40 13 
Temazepam 301 255.4 80 30 20 
  177.2 80 55 16 
Zolpidem 301 255.4 100 45 15 
  177.2 100 38 15 
Diazepam-d5 290 154.3 80 45 15 
Oxazepam-d5 292 246.3 70 30 12 
Zolpidem-d7 215 242.3 100 50 15 
Ketamine 238 125 60 38 20 
  207 60 20 33 
Norketamine 224 125.2 60 32 20 
  124.9 60 33 19.5 
Dehydronorketamine 222 141 40 35 23 
  114 40 75 18 
Ketamine-d4 242 129 60 53 21 
Norketamine-d4 228 211 125 53 10 
1The transition used for quantification are in bold. 
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Table 2-5 LC condition for the source and gas in Benzos and K group. 
  CUR CAD IV TEM GS1 GS2 
Benzos group 25 medium 5500 600 90 90 
K group 25 medium 5500 650 90 90 
 
 
3 RESULTS & DISCUSSION 
3.1 Specimen Contamination 
The urine specimens from female donors were examined microscopically on the 
first day and the last day of analysis to determine the bacterial growth.  Aseptic urine is 
nearly impossible due to the nature of the female excretory system and the urination 
process, however, the contamination level of the specimen was determined to be 0 among 
all donors as no bacteria cells were observed from the slides made on Day 0 and Day 210 
under a magnification of 400 times.  Figure 3-1 illustrates the microscopic slides made on 
Day 0 and Day 210 with FS under a magnification of 400 times, and there were no 
epithelial cells observed from the slides made from the FS samples.  The negative 
findings could be due to two reasons: (1) the average size of epithelial cells is 64 µm but 
the size of E. coli is only 1-3 µm, so 400 times magnification might not be sufficient to 
see the bacteria, and a microscope with higher magnifying power might be helpful, and (2) 
a special staining technique might be required to make the bacteria easier to observe even 
under low magnification. 
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(A)   (B)  
Figure 3-1 Images of urine specimen on Day 0 and Day 210 under 400 times 
magnification. (A from Day 0, B from Day 210) 
 
 All donated urine specimens were negative for the presence of the target 
compounds prior to any pre-treatment.  The solvent blanks were analyzed between 
samples to evaluate any potential carryover and contamination between every injection in 
the LC analysis.  
 
3.2 Benzodiazepines Group 
As previously mentioned, since this class of drugs shares the same benzene-
diazepine ring in structure, the polarity of different Benzos can be similar, which can 
cause poor separation in chromatographic analysis due to the similar interaction with the 
stationary phase.  The RT of each analyte was confirmed by running the analytes through 
the LC-MS/MS method individually to ensure a correct interpretation.  Table 3-1 
demonstrates that there was little difference in retention time (RT) between the selected 
Benzos, and only zolpidem could be separated apart from the other compounds, because 
there is no similarity in structure between Benzos and zolpidem. 
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Table 3-1 Compound identification of analytes in Benzos group. 
Compound RT1 ± RSD2 Compound RT1 ± RSD2 
Alprazolam 4.38 ± 0.000 Midazolam  3.38 ± 0.191 
Clonazepam  4.36 ± 0.110 Nordiazepam  4.40 ± 0.119 
Diazepam  5.24 ± 0.103 Oxazepam  3.86 ± 0.131 
Flunitrazepam 4.75 ± 0.127 Temazepam  4.63 ± 0.101 
Lorazepam  3.96 ± 0.118 Zolpidem  2.63 ± 0.245 
1Retention time (min) 
2Relative standard deviation (%) 
 
There were 10 analytes selected for this class of drugs to prove the concept of the 
effects from the FS collection method.  Figure 3-2 illustrates the chromatograph for this 
LC-MS/MS method.   
 
Figure 3-2 Chromatograph of the selected compounds in Benzos group. 
 
A linear calibration curve was used for the calculation with a weighting factor of 
1/x.  The curve stability, data quality and assay performance could be impacted by the 
weighting factors.  The linear regression is more likely administrated by the data at 
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higher concentrations, which causes errors at lower concentrations.  The data from lower 
concentrations is not fitted with the calibration curve, and the R2 value can be off the 
accepted limit.  Applying an appropriate weighting factor to the calibration curve can 
compensate the errors at lower concentrations to improve the quality of the calibration 
curve.  SCIEXâ MultiQuantä has a built-in analysis software that allows the operator to 
choose the optimal weighting factor, and 1/x gave the best results for the calibration 
curve of each analyte. (Figure 3-3)  The accuracy was set to be +/- 20% and a calculated 
value greater or less than +/- 20% was considered to be inaccurate. 
 
Figure 3-3 Calibration curve for all compounds with a weighting factor of 1/x.   The 
R2 value of each analyte was greater than the accepted limit of 0.98. 
 
 Figures 3-4 to 3-6 demonstrate that the concentrations of all analytes with the pre-
treatment of toluene decreased dramatically regardless of the storage conditions with at 
least 50% degradation.  This phenomenon indicated that 0.5% of toluene might be too 
high for the compounds of interest, and they were highly degraded.   
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Figure 3-4 The changes of analytes in concentration with toluene stored at 25°C 
(target concentration was 500 ng/mL). 
 
 
Figure 3-5 The changes of analytes in concentration with toluene stored at 4°C 
(target concentration was 500 ng/mL). 
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Figure 3-6 The changes of analytes in concentration with toluene stored at -20°C 
(target concentration was 500 ng/mL). 
 
Figure 3-7 shows the test tube from one of the samples pre-treated with toluene, a 
bent line was observed, and this phenomenon was observed from all test tubes.  Toluene 
didn’t dissolve in the specimens, and it accumulated in the layer on the top of the sample.  
Toluene also dissolved the tube forming a mark around the test tube.  Toluene and/or the 
organic materials dissolved from the tube might contribute the breakdown of the 
compounds.  The samples with toluene pre-treatment will not be further discussed due to 
the dramatic change in concentrations among all analytes.  
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Figure 3-7 Imprint mark on Falcon test tubes with toluene pre-treatment after 10 
days. 
 
Regardless of the preparations of FS or non-treated samples, the analytes were 
preserved the most when the samples were stored under -20°C, and they were preserved 
the least when stored at room temperature.  Clonazepam and flunitrazepam became 
undetectable after 30 days when the samples were stored at room temperature, but they 
were preserved when stored at 4°C. (Figures 3-8 to 3-13)  These findings revealed that 
high temperature accelerates the degradation among the selected analytes, but also 
demonstrated that the freeze-thaw cycles did not cause the degradation.   
 
Imprint	mark	
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Figure 3-8 The changes in concentration of analytes with filtration pre-treatment 
stored at 25°C (target concentration was 500 ng/mL). 
 
 
Figure 3-9 The changes in concentration of analytes with filtration pre-treatment 
stored at 4°C (target concentration was 500 ng/mL).  
 
 
 
0
100
200
300
400
500
600
700
0 20 40 60
Co
nc
en
tra
tio
n (
ng
/m
L)
Time (Day)
Samples with Filtration at 25°C 
Alprazolam
Temazepam
Flunitrazepam
Oxazepam
Lorazepam
Diazepam
Nordiazepam
Clonazepam
Midazepam
Zolpidem
0
100
200
300
400
500
600
700
0 20 40 60
Co
nc
en
tra
tio
n (
ng
/m
L)
Time (Day)
Samples with Filtration at 4°C 
Alprazolam
Temazepam
Flunitrazepam
Oxazepam
Lorazepam
Diazepam
Nordiazepam
Clonazepam
Midazepam
Zolpidem
		 32	
 
Figure 3-10 The changes of analytes in concentration with filtration pre-treatment 
stored at -20°C (target concentration was 500 ng/mL). 
 
 
Figure 3-11 The changes of analytes in concentration without pre-treatment stored 
at 25°C (target concentration was 500 ng/mL). 
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Figure 3-12 The changes of analytes in concentration without pre-treatment stored 
at 4°C (target concentration was 500 ng/mL). 
 
 
Figure 3-13 The changes of analytes in concentration without pre-treatment stored 
at -20°C (target concentration was 500 ng/mL). 
 
 Since the room temperature condition was not preferred for all the analytes, 
further analysis was performed to compare the changes between 4°C and -20°C storage 
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conditions. (Table 3-2)  The results from student t-test suggest that there was no 
significant difference in changes when the samples were stored at either temperature.  
Best preservation can be achieved when samples are stored in the freezer, but it is 
acceptable to be stored in the refrigerator depending on the equipment and policy in the 
individual laboratory. 
Table 3-2 Student t-test results for different storage conditions (target concentration 
was 500 ng/mL).  
Analyte Pre-Treatment 
Mean t-test3 
4°C -20°C 
Alprazolam FS1 341 362 59% 
 N2 329 354 58% 
Temazepam FS 556 522 10% 
 N 538 514 49% 
Flunitrazepam FS 391 454 42% 
 N 405 486 31% 
Oxazepam FS 472 488 40% 
 N 481 474 74% 
Lorazepam FS 476 465 63% 
 N 464 485 39% 
Diazepam FS 489 490 97% 
 N 496 494 91% 
Nordiazepam FS 516 516 99% 
 N 519 519 98% 
Clonazepam FS 372 498 9% 
 N 364 447 26% 
Midazolam FS 288 295 28% 
 N 313 253 6% 
Zolpidem FS 532 507 43% 
 N 535 526 81% 
1FS – filtration sterilization  
2N – no pre-treatment 
3A value of 5% or greater suggests that there is no significant difference between the populations. 
 
 Table 3-3 demonstrates that there is no significant difference in concentration 
between with filtration and without filtration when the samples were stored at the same 
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temperature, except for clonazepam.  The changes in concentration of each analyte 
behaved similarly between with and without filtration when the samples were stored at 
room temperature and in the refrigerator.  Under the condition of -20°C, there was no 
degradation of clonazepam in the filtration sample, but 10.5% degradation of clonazepam 
was observed in the control sample.  There were different degrees of degradation on each 
analyte, but the changes behaved similarly in the samples pre-treated with or without 
filtration technique, and no significant difference was observed. 
Table 3-3 Student t-test results for different pre-treatments (target concentration 
was 500 ng/mL). 
Analyte Pre-
Treatment 
25°C 4°C -20°C 
Mean t-test3 Mean t-test Mean t-test 
Alprazolam FS1 385  341  362  
 N2 361 47% 329 81% 354 80% 
Temazepam FS 527  556  522  
 N 552 34% 538 43% 514 80% 
Flunitrazepam FS 175  391  454  
 N 178 99% 405 89% 486 24% 
Oxazepam FS 386  472  488  
 N 420 68% 481 64% 474 51% 
Lorazepam FS 351  476  465  
 N 401 63% 464 66% 485 31% 
Diazepam FS 472  489  490  
 N 447 30% 496 79% 494 83% 
Nordiazepam FS 474  516  516  
 N 408 40% 519 88% 519 87% 
Clonazepam FS 175  372  498  
 N 174 100% 364 93% 447 3% 
Midazolam FS 277  288  295  
 N 255 37% 313 23% 253 6% 
Zolpidem FS 576  532  507  
 N 553 9% 535 92% 526 61% 
1FS – filtration sterilization  
2N – no pre-treatment 
3A value of 5% or greater suggests that there is no significant difference between the populations. 
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Table 3-4 demonstrates the difference between the extracted and unextracted 
samples, and the recovery was more than 50% for most of the analytes except midazolam 
and zolpidem.  The recovery of midazolam was low for both 50 ng/mL and 200 ng/mL 
samples, with 46% recovery from the 50ng/mL samples and 31% recovery from the 200 
ng/mL samples.  The SPE procedure might not be preferred by midazolam, and further 
optimization is needed.  However, the recovery of zolpidem for 50 ng/mL samples was 
50% lower than the 200 ng/mL samples.  Two 50 ng/mL zolpidem samples were 
undetectable, and one was only quantified at 9 ng/mL.  Random error was ruled out since 
three samples were calculated at a very low concentration.  This SPE method is specific 
for Benzos, because the chemical property of zolpidem is different from Benzos, and the 
elution solvent might not be strong enough to elute zolpidem, or zolpidem could be 
washed off during the washing step before elution.  The other possibility is this SPE 
method favors zolpidem at the high concentrations, which is most likely since almost 
50% recovery was achieved at the 200 ng/mL samples, and this instability can cause 
inaccuracy in quantification. 
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Table 3-4 Extraction recovery of selected Benzos. 
Analyte 
Mean (50 ng/mL) 
Recovery 
Mean (200 ng/mL) 
Recovery Unextracted1 Extracted2 Unextracted Extracted 
Alprazolam 60 31 52% 250 126 51% 
Temazepam 62 58 93% 218 166 76% 
Flunitrazepam 56 42 76% 244 205 84% 
Oxazepam 51 32 62% 202 172 85% 
Lorazepam 48 32 67% 149 134 89% 
Diazepam 65 49 75% 189 145 77% 
Nordiazepam 55 53 96% 250 204 82% 
Clonazepam 52 45 85% 246 155 63% 
Midazolam 59 27 46% 255 79 31% 
Zolpidem 56 9 17% 205 91 44% 
1Unextracted – analytes were added after the extraction step 
2Extracted – analytes were spiked in the negative urine, and performed normal SPE procedure 
 
3.2 Ketamine Group 
Norketamine (NK) and dehydronorketamine (DNK) are the metabolites of 
ketamine (K), and the poor separation in the chromatographic analysis can be expected 
due to the similarity of structure, polarity and property as mentioned previously.  
Therefore, compound identification was the first step in analysis after the optimization 
steps were completed to ensure the correct interpretation. (Table 3-4)    
Table 3-5 Compound identification of analytes in K group. 
Compound RT1 ± RSD2 
Ketamine 1.87 ± 0.289 
Norketamine 1.70 ± 0.177 
Dehydronorketamine 1.61 ± 0.323 
1Retention time (min) 
2Relative standard deviation (%) 
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Theoretically, the calibration curve for K was established based on the calculation 
of the peak area (concentration) of K-d4 (IS), and the calibration curve for NK and DNK 
was established based on the calculation of the peak area (concentration) of NK-d4 (IS).  
NK-d4 was not detected by LC-MS/MS from all the samples (Figure 3-14) and the 
absence of NK-d4 did not affect the detection and quantification of the K group.  The 
elution time of K, NK and DNK were within 0.6 min in the 3-min method, and the R2 
value was greater than 0.99 for all the calibration curves.  Therefore, K-d4 was sufficient 
for the analysis of K and metabolites by using this method.   
(A)  (B)  
Figure 3-14 The absence of NK-d4 in LC-MS analysis. (A is neat, B is sample) 
 
The calculated concentrations with a range of +/- 20% of K and metabolites, and 
the calibration curve was established with a weighting factor of 1/x to lower the overall 
error. (Figure 3-15)  There was a shortcoming in the analysis of K group in that the 
original instrumental analysis was an 8-min method, and it had been optimized to a 3-min 
method while the samples were aging.  K is very stable in biological samples, and the 
initial analysis was designed to be performed after a 5-month storage.  A set of samples 
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were prepared at the same concentration, extracted by the same SPE method and 
analyzed by using the 3-min method to estimate the Day 0 concentration.  These initial 
concentrations were only used to demonstrate the changes in concentrations over time, 
and they did not represent the actual initial concentrations of the samples.  
 
Figure 3-15 Calibration curve of all analytes with a weighting of 1/x. 
 
 The degradation caused by toluene in the Benzos group was not observed in the K 
group, and the high temperature condition did not contribute to the degradation. (Figures 
3-16 to 3-21)  However, DNK decreased dramatically after 150 days regardless of the 
pre-treatment methods or the storage conditions.  This phenomenon revealed that K and 
NK are very stable in urine not only at various temperatures, but also in an organic 
environment.  Dehydronorketamine is the dehydration product of NK, and it undergoes 
biotransformation to glucuronide conjugates in an acid environment; human urine is a 
neutral to acidic liquid that can cause the degradation of DNK.   
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Figure 3-16 The changes of ketamine and metabolites with filtration stored at 25°C 
(target concentration was 500 ng/mL). 
 
 
Figure 3-17 The changes of ketamine and metabolites with filtration stored at 4°C 
(target concentration was 500 ng/mL). 
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Figure 3-18 The changes of ketamine and metabolites with toluene pre-treatment 
stored at 25°C (target concentration was 500 ng/mL). 
 
 
Figure 3-19 The changes of ketamine and metabolites with toluene pre-treatment 
stored at 4°C (target concentration was 500 ng/mL). 
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Figure 3-20 The changes of ketamine and metabolites without pre-treatment stored 
at 25°C (target concentration was 500 ng/mL). 
 
 
Figure 3-21 The changes of ketamine and metabolites without pre-treatment stored 
at 4°C (target concentration was 500 ng/mL). 
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However, the concentrations of K and NK from the samples stored in freezer 
decreased about 50% compared to the concentrations found on Day 150. (Figure 3-22 to 
3-24)  The freeze-thaw cycles should not cause the degradation, and this phenomenon 
was observed from all samples regardless of the pre-treatment methods.  Further 
investigation on pH may explain why the pH was higher in all urine that was stored at 
room temperature and lower in samples stored in refrigerator and freezer. (Table 3-5)  
The initial pH of each urine specimen was not measured, but the changes behaved 
similarly under each condition regardless of donors and the time of aging.  The pH 
increased to 8.5 when the specimens were stored at room temperature, which is outside of 
the pH range of normal human urine.  There was no significant difference in pH between 
specimens stored in the refrigerator and freezer, and the pH fell within the range of 
normal human urine.  Compounds were preserved better under low temperature 
conditions in general, and this phenomenon indicated that temperature affected pH, 
which contributed to compound degradation.  
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Figure 3-22 The changes of ketamine and metabolites with filtration stored at -20°C 
(target concentration was 500 ng/mL). 
 
 
Figure 3-23 The changes of ketamine and metabolites with toluene pre-treatment 
stored at -20°C (target concentration was 500 ng/mL). 
 
0
100
200
300
400
500
600
0 50 100 150 200 250
Co
nc
en
tra
tio
n (
ng
/m
L)
Time (Day)
Samples with Filtration Stored at -20°C
Ketamine
Dehydronorketamine
Norketamine
0
100
200
300
400
500
600
0 50 100 150 200 250
Co
nc
en
tra
tio
n (
ng
/m
)
Samples with Preservative Stored at -20°C
Ketamine
Dehydronorketamine
Norketamine
		 45	
 
Figure 3-24 The changes of ketamine and metabolites without pre-treatment stored 
at -20°C (target concentration was 500 ng/mL). 
 
Table 3-6 pH measurements. 
 
25°C 
 
4°C -20°C 
B1 K2 B K B K 
pH 
8.76 8.25 6.74 6.71 6.38 6.28 
8.35 8.66 6.86 6.78 6.64 6.62 
8.43 8.41 6.68 6.68 6.81 6.23 
Mean 8.51 8.44 6.76 6.72 6.61 6.38 
S.D.3 0.22 0.21 0.09 0.05 0.22 0.21 
t-test4 69% 58% 25% 
1B – Urine used in Benzos group 
2K – Urine used in K group 
3S.D. – Standard deviation 
4A value of 5% or greater suggests that there is no significant difference between the populations. 
 
The recovery of this SPE procedure achieved more than 70% of recovery in K and 
NK, and about 40% recovery of DNK. (Table 3-6)  Dehydronorketamine is less polar 
than K and NK due to the loss of two hydrogens, and easily washed through the column.  
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But the recovery was consistent between different concentrations, which would not cause 
inaccuracy in quantification that the Benzos group might have.  
Table 3-7 Extraction Recovery of Ketamine and metabolites. 
 
Mean (50 ng/mL) 
Recovery 
Mean (200 ng/mL) 
Recovery Unextracted Extracted Unextracted Extracted 
K 63 52 82% 262 201 77% 
NK 55 25 44% 220 101 46% 
DNK 57 47 82% 217 189 87% 
 
Regardless of the compounds studied in this project, compound breakdown 
caused by toluene and temperature effects have been discussed, but the effects of FS were 
unclear.  The decreasing rates from the FS pre-treated samples were similar to the 
samples without any pre-treatment, and there are several possibilities to explain this.  
Theoretically, the filters were sufficient enough to filter E. coli since the pore size of the 
membrane is 0.2 µm compared to 1 µm, the smallest average size of the cross section of 
E. coli.  Therefore, the first possibility is that most of the E. coli cells had smaller size 
than the average value, and the contamination level in the FS pre-treated samples was the 
same as the non-treated samples over time due to the incomplete removal of bacteria.  
The degradation in both samples was the same since the bacterial levels were the same, 
and the decreasing rate was the same among with and without FS pre-treated samples.  
The second possibility is that there were other types of bacteria in the urine causing 
compound degradation, and their size was much smaller than 0.2 µm.   The last 
possibility is that bacterial contamination was not one of the factors contributing to 
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compound degradation, therefore, compounds could degrade even in a bacteria free 
sample.   
pH could be a factor effecting degradation.  The amount of bacterial 
contamination and the pH value are varied between individuals, and the effect of pH was 
not studied in this project.  The pH level of human urine is between 6.5-8 depending on 
the time tested, ingested food substances consumed and medical history.  Chemical 
compounds are sensitive to pH, and as discussed previously, pH did change over time 
with different rates under different temperatures, therefore, pH is believed to be the major 
reason contributing to compound degradation. 
 
4 CONCLUSIONS 
From the results of the microscopic examination, the amount of epithelial cells 
was reduced dramatically, which revealed that the filters functioned properly.  However, 
no bacterial cells were observed from all of the slides from Day 0 to the last day of 
analysis regardless of the staining technique.  Therefore, it could not be concluded that 
the selected filters could purify or semi-purify the urine specimens by filtrating out the 
bacterial cells. 
In the investigation of the effects of different preservation methods on the stability 
of different classes of drugs, the concentrations of the samples pre-treated with toluene 
decreased much more than the other groups, from which it can be concluded that toluene 
is not suitable for the compounds studied.   By comparing the samples pre-treated with 
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and without filtration, there was no difference found regardless of the storage conditions 
and the compounds.  Therefore, the effect of filtration sterilization is unclear. 
 
5 FUTURE DIRECTIONS 
The microscopic results did not reveal the presence of bacteria, and the reasons 
have been previously discussed.  Two fields can be studied to improve the results. An E. 
coli or bacteria specific staining technique can be utilized to make the bacterial cells more 
distinctive from the epithelial cells and visible under a mid-range magnification 
microscope. Utilization of a high magnifying power microscope (1000 times 
magnification) to examine the urine specimens is another option.  However, a high-range 
microscope is expensive, and not every laboratory has access to one.   
The bacterial contamination level might not be the major factor that affected the 
compound degradation, and pH may be the primary reason, as discussed previously.  One 
of the future studies could be the evaluation of the pH effect on compound stability.  
However, it is necessary to confirm the absence of bacteria in the specimen for which 
filtration has been performed prior to the evaluation of the pH effect(s).  Bacterial 
contamination must be ruled out from compound degradation, so that the concentration of 
target compounds could be compared with the changes in pH over time.   
Benzodiazepines and ketamine are two classes of drugs with similar effects, and 
these effects can be enhanced when combined.  It is a good interaction for patients 
because they can get the optimal effect with a lower dose, but this is also good to sexual 
assailants because the adverse effects are greater.  It is common to detect more than one 
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class of drugs in DFSA crimes, therefore, one of the future studies can be the 
development of an analytical method to detect and quantify both classes of drugs, or an 
analytical method to detect all Benzos with better separation and resolution since there 
are many Benzos that have been reported in DFSA crimes. 
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